{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.09","value":"172.6"},{"groupId":"OG001","spread":"85.38","value":"175.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"The Peripheral Neuropathy Questionnaire was used to analyze this endpoint. Patient neuropathy symptoms were scored on a 0 - 100 scale (higher score represents less symptomatic). The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported.","dispersionType":"Standard Deviation","groups":[{"description":"Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks. Baclofen/amitriptyline/ketamine gel: Applied topically.","id":"OG000","title":"Baclofen-amitriptyline Hydrochloride-ketamine"},{"description":"Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks. Placebo: Applied topically","id":"OG001","title":"Placebo"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to 4 weeks","title":"Numbness, Tingling, and Pain as Measured by the Peripheral Neuropathy Questionnaire at Baseline and Weekly for 4 Weeks","type":"SECONDARY","unitOfMeasure":"units on a scale * week"}